Mechanisms of Inflammation in Post-Operative Recurrence of Crohn’s Disease Authors: Hadley Greenwood, Calen A Steiner, Benjamin Click Published: 2026 ABSTRACT AbstractDespite advances in guideline-directed surveillance and initiation of biologic therapy after ileocecal resection for Crohn’s disease, many patients still experience post-operative recurrence. There is a growing field of research on the mechanisms of inflammation that are specific to post-operative recurrence after surgical resection and anastomosis. Within the innate immune system, certain genetic risk factors and an imbalance in matrix metalloproteinases have been implicated; however, the roles of specific innate immune cells are still being studied. Within the adaptive immune system, increased T-cell clonal expansion at the time of surgery and specific antibodies may play important roles in inflammation after resection. There are emerging associations to link mitochondrial oxidative stress, specific chemokines and cytokines, and microbial dysbiosis to the processes driving post-operative inflammation.Keywords: post-operative recurrence, inflammatory pathways, T-cells, microbial dysbiosis Introduction Crohn’s disease (CD) is a chronic inflammatory bowel disease that has a relapsing and remitting course and is characterized by inflammation of the gastrointestinal tract, most classically transmural and in a skip lesion distribution. It can be phenotypically classified as inflammatory, stricturing, or penetrating and presenting symptoms can include abdominal pain, diarrhea and weight loss, along with a host of extra-intestinal manifestations. Despite advances in biological therapies, it is estimated that up to 40–50% of patients with CD will require surgical resection within the first decade following diagnosis, and up to 14.8% will require repeat surgical resection five years after index resection.1,2 The pathogenesis of CD is complex and includes the interplay between genetics, gut microbiota, barrier dysfunction, and an aberrant host immune response. Decades of research have led to a relatively robust understanding of the role of the immune system and inflammatory cells in maintaining active disease, with many CD therapies directed at discrete elements of the inflammatory pathways. Little is known about the mechanisms of inflammation specific to post-operative recurrence (POR) of CD after surgical resection and anastomosis. Recent studies have begun to shed light on the specific inflammatory pathways that drive tissue destruction and eventual POR after resection. Risk factors for POR include an increased proportion of T-cell clonal expansion at the time of surgery, modifications to the gut microbiota, and specific gene signatures.3–5 These findings, in conjunction with emerging mechanistic understanding of specific processes driving inflammation in the post-operative setting, are anticipated to improve the development of treatments and strategies for post-operative CD recurrence. Figure 1 presents an overview of the mechanisms of inflammation in POR, which will be covered in this review. Emerging associations specific to post-operative inflammation highlighted include Mothers against decapentaplegic homolog 3 (SMAD3) risk alleles and pathological fibrosis at the anastomotic site, an imbalance of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) in mucosa after resection, and increased T-cell clonal expansion at time of surgery. Overview of mechanisms of inflammation in POR. Investigation of gene expression profiles and risk alleles have implicated multiple key genes which may serve as potential biomarkers in POR of CD.5–7 An imbalance between MMPs and TIMPs may also have a role in the pathogenesis of CD.8,9 Cells of the innate immune system, such as neutrophils, dendritic cells, and macrophages, have emerging associations with specific inflammatory processes of POR although the specific mechanisms have yet to be fully elucidated. Increased T-cell clonal expansion at time of surgery and Fla-X and GM-CSF antibodies have been associated with increased risk of POR.3,5,10–13 Gut microbiota are further characterized in Figure 2. Cytokines such as TNF-α, IL-23A and IL-17A have been found to be upregulated in endoscopic recurrence.5,14–17 Mitochondrial pathways are also implicated, with oxidative stress promoting downstream inflammation.5,7 Abbreviations: TIMPs, tissue inhibitors of MMPs; Anti-Fla-X, flagellin subunits, Clostridium derived antibodies; GM-CSF Ab, granulocyte-macrophage colony-stimulating factor antibodies; AIEC, adherent-invasive E. coli; TNF-α, tumor necrosis factor alpha; IL, interleukin; CXCL, Chemokine (C-X-C motif) ligand. Innate Immune System Within the innate immune system, several factors have been implicated in post-operative recurrence, including certain genetic risk factors and an imbalance in matrix metalloproteinases (MMPs), which are endoproteinases that act as key regulators in the inflammatory process. Multiple cell types also play a role, but the contributions of various cell types have yet to be clearly delineated. Genetic Polymorphisms and Risk Alleles Exploration of gene expression profiles implicated in the POR of CD is underway. Table 1 summarizes the various genes and their proposed mechanisms of action in POR. Table 1Gene Expression Profiles Implicated in Post-Operative Recurrence of Crohn’s DiseaseSpecific Element(s)Proposed Mechanism of ActionStudy BackgroundNOD2 (SNP rs2066844)18,19Inappropriate activation of innate immune cellsRef18 &:19 Retrospective cohort studiesSMAD320Pathologic fibrotic and scarring after surgeryRef:20 observational study (retrospective and prospective)PLOD2, ZNF165, ARMCX47Co-expressed with STAT3, increased JAK/STAT pathway activationRef:7 Single study analysis of ileal mucosal samplesSTAT35,21,22Excess activation and prolonged survival of pathogenic T cellsRef:5 multicenter prospective studyAhR pathway5,23,24Downregulation of pathway impairs maintenance of intestinal homeostasis, increases pro-inflammatory cytokinesRef:5 multicenter prospective studyCARD825,26Incomplete or improper suppression of NF-κB activationRef:26 observational study (retrospective and prospective)BACH227Mutation predisposes to lose of immunotoleranceRef:27 observational study (retrospective and prospective)Abbreviations: NOD2, Nucleotide-binding oligomerization domain-containing protein 2; SMAD3, Mothers against decaptaplegic homolog 3; PLOD2, Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2; ZNF165, Zinc finger protein 165; ARMCX4, Armadillo repeat containing X-lined 4; STAT3, Signal transducer and Activator of Transcription 3; AhR, Aryl hydrocarbon receptor; CARD8, Caspase recruitment domain-containing protein 8; BACH2, BTB domain and CNC Homolog 2. Gene Expression Profiles Implicated in Post-Operative Recurrence of Crohn’s Disease Abbreviations: NOD2, Nucleotide-binding oligomerization domain-containing protein 2; SMAD3, Mothers against decaptaplegic homolog 3; PLOD2, Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2; ZNF165, Zinc finger protein 165; ARMCX4, Armadillo repeat containing X-lined 4; STAT3, Signal transducer and Activator of Transcription 3; AhR, Aryl hydrocarbon receptor; CARD8, Caspase recruitment domain-containing protein 8; BACH2, BTB domain and CNC Homolog 2. Pattern recognition receptors (PRRs) are proteins expressed on innate immune cells (IICs) and allow the identification of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).6,28 PRRs, which include toll-like receptors (TLRs), are able to initiate immune responses, marking an important early stage of inflammation.6 NOD2/CARD15 is an intracellular PRR implicated in CD pathogenesis.29,30 Patients carrying gene variants may have increased and earlier need for first surgery.30 Similarly, NOD2/CARD15 mutations have been associated with higher surgical recurrence rates (OR 3.29; 95% CI 1.13–9.56) and earlier time to repeat surgery in both adult and pediatric cohorts.30–34 This effect may be further mediated by smoking.35 A particular NOD2 single-nucleotide polymorphism (SNP), rs2066844, has been demonstrated to be independently associated with CD recurrence.18,19 SMAD3 encodes a protein mediator in the Transforming Growth Factor-beta (TGF-β) signaling pathway. SMAD3 homozygosity for a CD-associated risk allele has been identified as an independent predictor of POR, with shorter time to repeat surgery and increased need for repeat operation.20 Fowler et aldemonstrated this using Cox proportional hazards models to adjust for potential confounders and reported SMAD3 homozygosity for the risk allele was significantly associated with need for repeat surgery (HR 488, 95% CI 2.26–10.53).20 The proposed mechanism involves the role played by TGF-β, a multifunctional cytokine involved in cell growth and differentiation, immune cell function, and extracellular matrix production.36 TGF-β plays a complex role in Crohn’s disease: although it is considered a negative regulator of intestinal inflammation, it has paradoxically been found to be increased in intestinal tissues of CD patients. This duality is thought to be related to dysregulated signaling and increased fibrotic response.37,38 SMAD3 murine knockout studies have shown decreased expression of TGF-β as well as diminished fibrotic response.39,40 Although speculative, Fowler et al proposed that the SMAD3 risk allele they identified may present a mechanism of inflammation unique to CD after index surgery if the mechanism of injury involves defective TGF-β signaling, pathological fibrosis, and impaired wound healing at an existing injury (the surgical site). If further study identifies mechanistic evidence, the association between SMAD3 risk alleles and an increased risk of surgical POR in CD could represent a future therapeutic target at sites of post-operative fibrotic/stricturing disease recurrence.20 Rajalingam et al studied ileal mucosa samples from the neo-terminal ileum six months after surgery using machine learning algorithms to identify five key genes linked to POR: Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2), zinc finger protein 165 (ZNF165), BCL-2-related ovarian killer (BOK), C-X-C motif chemokine receptor 1 (CXCR1), and Armadillo repeat containing X-lined 4 (ARMCX4).7 These genes are involved in a multitude of functions, including interaction with cytokine receptors, apoptosis, G protein-coupled chemoattractant receptor activity, and regulation of mitochondrial depolarization. PLOD2, ZNF165, and ARMCX4 are co-expressed with STAT3 and IL-5; the former is well recognized for its involvement in various autoimmune disorders and will be discussed further in the context of the JAK/STAT pathway, while IL-5 is involved in innate and acquired immune regulation through activation of B cells and eosinophils.41 Thus, activation of these potential biomarkers in these ileal mucosal samples is linked to downstream inflammatory pathways involved in POR. Tissue transcriptome analyses from the ileal surgical margin and later from the neo-terminal ileum 6 months after ICR have shown a significant increase in STAT3 expression and phosphorylation at the ileal margin in patients who developed early and severe endoscopic POR.5 STAT3 is a major protein in the JAK/STAT signaling pathway, which is critical in regulation of T-cell differentiation among other roles and has been suggested to contribute to excessive T cell activation and intestinal mucosa infiltration in CD.42 Earlier studies have demonstrated that STAT3 activation by the pro-inflammatory cytokine IL-6 can lead to prolonged survival of pathogenic lamina propria T cells, ultimately propagating intestinal inflammation.21 STAT3 shows potential to be a central protein in predicting development of POR and may represent a potential therapeutic target, with exploration of the potential role for STAT3 inhibitors ongoing.5,22 Genetic expression analysis has also identified two signaling pathways, aryl hydrocarbon receptor (AhR) and peroxisome proliferator-activated receptor (PPAR), in which downregulation is associated with a higher risk of POR.5 The AhR pathway helps maintain intestinal homeostasis via IL-2. PPAR gamma ligands are thought to downregulate the production of pro-inflammatory cytokines. Activation of these pathways has been proposed as an area of further investigation for the prevention of POR.23,24 Other genes that have been implicated in the POR of CD include caspase recruitment domain-containing protein 8 (CARD8), a key player in innate immunity and regulator of the inflammasome, and BTB domain and CNC homolog 2 (BACH2), which are involved in the proper differentiation of B and T cells, as well as maintaining immune homeostasis.25–27 Notable limitations of existing genetic pathway data in POR include application in real-time clinical practice due to the complexity of technology and analyses, as well as ongoing exploration of mechanistic findings correlative to associative findings. MMPs Matrix metalloproteinases (MMPs) are endoproteinases that serve as key regulators of inflammation because of their proteolytic cleavage of inflammatory mediators.43 MMPs are secreted by inflammatory cells, such as macrophages and neutrophils, and most are transcriptionally upregulated in inflammatory states. In inflammatory bowel disease (IBD), upregulation of MMP1 and MMP10 corresponds to increased severity of inflammation.43–45 Although MMP activity is regulated at several levels, an imbalance between tissue inhibitors of MMPs (TIMPs) and MMPs is thought to play a role in the pathogenesis of CD. Specifically in POR of CD, higher expression of TIMP levels in mucosa after resection has been shown to be protective against POR.8 Furthermore, in a 2022 study of inflammation-related proteins associated with CD recurrence, Walshe et al found that MMP1 and MMP10 were significantly associated with increasing endoscopic disease activity on post-operative colonoscopy.9 Taken together, there is a clear case to be made for the role of MMPs in inflammation in POR of CD, although the specific mechanisms of upregulation of certain MMPs specific to POR are still unclear. Cells of the Innate Immune System Neutrophils are a primary contributor in acute inflammation.46–48 Neutrophilic functions contribute to inflammation of CD, including damage to the intestinal epithelium and intestinal mucosal barrier function due to release of neutrophil extracellular traps, myeloperoxidase, acidification, and direct tissue damage from release of MMPs and neutrophil elastase with resulting high levels of reactive oxygen species.49–52 Their role in the disruption of crypt architecture and generation of crypt abscesses has been well recognized.53,54 However, there is a dearth of data on neutrophil activity in inflammation specific to post-operative recurrence and this remains an area for future study. Macrophages play a critical role in tissue homeostasis.55–58 They are implicated in CD pathogenesis when the balance is tipped too far in the direction of pro-inflammatory cytokine production, fibrogenic response, epithelial tissue disruption, and generation of granulomas.59–61 Multiple studies have shown increased numbers of pro-inflammatory macrophages in IBD patients, often with high expression of pro-inflammatory molecules, including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and inducible nitric oxide synthase.62–65 One subset of macrophages, called CX3CR1 macrophages, is a resident mucosal cell that typically captures luminal bacteria in an anti-inflammatory effort. CX3CR1 macrophages have been specifically implicated in CD inflammation, with studies showing upregulation in the colon of IBD mice.54,66 Recent experimental models have shown that CX3CR1 macrophages can traffic bacteria to mesenteric lymph nodes, ultimately inducing a downstream inflammatory process.67 Further, the neo-terminal ileum mucosa contains high numbers of macrophages before transition to endoscopic recurrence.68 Taken together, these findings highlight the role of macrophages in POR, and further study is needed. The role of dendritic cells, antigen-presenting cells of the innate immune system, in CD pathogenesis includes activation of Th1 and Th17 responses and dictation of the CD phenotype by the direction of effector T cells to target tissues via homing marker expression.69–72 Single-cell transcriptomic data highlight the role of dendritic cells in the POR of CD. Multiple serum proteins expressed on dendritic cells, including CXCL9, CXCL11, and PDL1, were associated with increased endoscopic disease activity.9 PDL1 binds to the PD-1 receptor on immune cells, providing inhibitory signals to suppress T cell activity.73 The positive association between PDL1 and endoscopic activity was proposed to represent increased PDL1 signaling by innate immune cells as a compensatory mechanism to overcome POR inflammation. In comparison, some of the other proteins positively associated with endoscopic inflammation (eg, CXCL9 and CXCL11) are thought to represent mechanisms of “breakthrough” inflammation via the CXCR3 axis, given that the association was found specifically in patients with post-operative anti-tumor necrosis factor exposure.9 Thus, modification of T cell responses by dendritic cells is likely a key mechanism in the POR of CD. Acquired Immune System The acquired immune system facilitates immunological memory by activating lymphocytes via antigen-specific responses. Lymphocytes include B cells responsible for humoral immunity and T cells, which act as effector or memory cells and interact closely with innate immune cells during inflammatory responses. Chronic inflammation in CD is thought to correlate with a breakdown in the balance of regulatory and effector T cell functions, with excessive inflammatory immune responses presumably triggered by and directed at the intestinal microbiota.74,75 The role of aberrant immune responses and immune memory has been an area of ongoing research in attempts to understand the pathogenesis of POR after surgical resection in CD. T Cells Two types of effector T cells that have been implicated in CD recurrence pathogenesis include TH1 and TH17 cells.54,70,76 They function to activate macrophages and enhance neutrophil responses, and represent a crucial link between the innate and adaptive pathways in inflammation-driven POR. At time of surgery, increased T-cell clonal expansion has been linked to increased risk of POR, and these clones that persist after ICR are thought to lead to an inflammatory state at the ileal margin even in the absence of histologic inflammation.3,5,10 Allez et al identified an association between smoking and clonal T cell expansions, suggesting smoking behavior was a causal factor in specific changes in the T cell repertoire leading to clonal expansion contributing to POR3 A study characterizing T-cell repertoires in a comparison between the neoterminal ileum of CD patients with POR and the ileum of healthy controls demonstrated expansion of certain T-cell populations in inflamed intestinal mucosa notably different from clones in the healthy tissue, lending further support for the pathogenic role of these highly expanded T cell clones in intestinal inflammation.11 There were 7 clonotypes in the TCR-ß sequences that were more common in CD tissues, with the most frequent TCR-ß clonotype identified as CASSWTNGEQYF (TRBV10-1-TRBJ2-7) and found to be significantly correlated with severity of CD recurrence.11 Clonal expansions of CD4+ NKG2D T cells in the intestinal mucosa of CD patients exhibit cytotoxic and pro-inflammatory properties, which include expression of high amounts of TNF-a. The presence of these clones in the non-inflamed ileal tissue of the surgical specimen at the time of resection may predict CD POR in the neo-terminal six months after surgery based on their findings.10 The association between myenteric plexitis or the accumulation of immune cells around the enteric ganglia and post-operative recurrence has previously been identified, and myenteric plexitis is included in some major guidelines as a risk factor for POR.77,78 In 2025, Le Berre et al demonstrated the specific role of T cells in this process. They showed that CD4 and CD8 T lymphocytes adhere to enteric glial cells and that these interactions promote the survival of T cells and the overall formation of plexitis.79 The leading theory behind the role of T cells in POR of CD relies on the persistence of pathogenic memory T cell clones in mesenteric lymph nodes, where they can outlast surgical resection before being recruited back to the neoterminal ileum through homing mechanisms to induce immune reactivation and ultimately recurrence.54 Magnetic resonance enterography studies of MLN enhancement have been shown to predict CD disease activity.80 Extended mesenteric excisions at the time of surgery have been proposed as a potential intervention to reduce recurrence; however, recent prospective trials have failed to demonstrate significant benefit.81–83 Ultimately, further investigation is needed and exploring targeted mesenteric resection during surgery and trafficking blocking strategies through drug development have become prominent areas of interest for researchers focused on preventing post-operative CD recurrence.84,85 Similarly, sphingosine-1-phosphate (S1P) receptor modulators are an emerging novel therapy in IBD.86–88 Their primary mechanism of action inhibits infiltration of lymphocytes into the gut mucosa, effectively trapping them in lymph nodes to prevent inflammation.89,90 Recognizing the role T cell clones residing in MLNs play in inflammation in POR, S1P receptor modulators may represent a promising future therapy for prevention and treatment of POR with additional study and high quality RCTs. BACH2 plays a critical role in T-cell differentiation, binding enhancers associated with effector T-cell differentiation, and reducing the induction of inflammatory cytokines.91,92 Without mutations, BACH2 is thought to support immunotolerance and contribute to immunological memory differentiation of long-lived memory CD8+ T cell responses.91,93 Laffin et al identified BACH2 as an independent risk locus for POR in a 2018 cohort study, hypothesizing that a mutation at this locus predisposes to an inappropriate inflammatory response, primarily because of the role of T cells and immunologic memory.27 Antibodies To date, the most explored contribution of humoral immunity to post-operative inflammation comes in the form of antibodies. Some promising studies have examined serological antibodies as markers of recurrence, although the pathophysiology of antibody development underlying these associations has not been fully elucidated. Some antibodies that have been previously associated with IBD include Anti-Saccharomyces cerevisiae antibodies (ASCA), perinuclear antineutrophil cytoplasmic antibodies (pANCA), antibodies to intestinal goblet cells, and antibodies against exocrine pancreatic antigens (rPag1 and rPag2).94–100 The most studied immunoglobulins are pANCA and ASCA, with reports that both are good serological markers for CD.54 ASCA, which targets the mannan protein from the yeast Saccharomyces cerevisiae, has been associated with more complicated CD behavior.97,101,102 Post-operatively, ASCA levels tend to remain stable and are not predictive of endoscopic or surgical recurrence.12,103 Fla-X (flagellin subunits, Clostridium derived) and GM-CSF (granulocyte-macrophage colony-stimulating factor) antibodies have been specifically implicated in CD recurrence. In an assessment of serological profiles post-operative predicting subsequent recurrence, Hamilton et al reported that anti-Fla-X positivity at baseline was associated with a higher risk of early post-operative CD recurrence and up to 18 months after ICR.12 CM-CSF autoantibodies neutralize the bioactivity of GM-CSF, which plays a crucial role in maintaining intestinal homeostasis through protective cytokine signaling. It enhances innate immune responses to microbial pathogens and mouse models studying deficiency of GM-CSF have shown resultant mucosal inflammation.104–106 Gathungu et al found in 2018 that patients with elevated GM-CSF auto-antibody levels had a shorter time to second surgery.13 Further research may allow the identification of immunoglobulins that can predict disease behavior post-operatively, as well as shed light on the pathophysiological mechanisms of antibody development in POR. Other Mechanisms of Inflammation The Role of Gut Microbiota CD is characterized by reduced bacterial diversity, loss of beneficial Firmicutes, and enrichment of Proteobacteria.107 Post-operatively, a shift in the microbiome may be influenced by operative trauma, bowel preparation, antibiotics, diet, and localized immune responses. These factors result in increased colonization by more aggressive species.108–110 Overall gain in pro-inflammatory pathogenic and reduced short-chain fatty acid producing bacteria in the post-operative period have been linked to POR, with such dysbiosis often preceding endoscopic recurrence.111–113 Other general trends associated with POR include a reduction in microbiota alpha diversity, supporting a relationship between decreased diversity and the intestinal inflammatory process.4,114 Although studies on gut microbiota profiles in POR have not always been consistent in their findings, some promising signatures have arisen.112 These are summarized in Figure 2. A 2020 large prospective multicenter study analyzed gut microbiota using 16S rRNA sequencing at the time of resection or the time of ileocolonoscopic evaluation within one year after surgery and identified bacterial taxa at the time of surgery associated with endoscopic POR.4 The gut microbiota present at the time of surgery, which were predictive of POR in this study, included bacteria from the Gammaproteobacteria, R. gnavus group, and Corynebacterium genera. Hernández-Rocha et al identified increased risk of ePOR in patients with an increase of several taxa from class Gammaproteobacteria, including Klebsiella and Escherichia-Shigella, and depletion of genus Anaerostipes114 A 2022 study highlights the association between endoscopic POR of CD and recolonization of the neoterminal ileum by pathogenic microbiota such as Escherichia coli (E. coli), Bacteroides, and Fusobacteriaceae.115 Other studies on microbial factors in POR have implicated the genus Proteus specifically, within class Gammaproteobacteria which has been more broadly implicated as above.111 Microbiota signatures identified in POR. Abbreviations: ICR, ileocecal resection; POR, post-operative recurrence. Valibouze et al studied adherent-invasive E coli (AIEC), which is one pathogenic species linked to POR, with findings that identified a probiotic yeast – Saccharomyces cerevisiae CNCM I-3856 – as a promising new candidate for prevention of POR in AIEC-infected CD patients based on a rat model of POR after ICR.116,117 A specific FimH gene blocker, TAK-018, was developed to target bacterial adhesion of AIEC and a clinical trial to study it as a potential treatment for prevention of CD POR was initiated but terminated early.118,119 Fusobacteria were previously shown in 2020 by Machiels et al to be the most prominent microbial player driving early POR. Machiels et al highlighted significant differences in microbiota recolonization after ICR in patients with and without recurrence. Remarkably, their analysis showed that the mucosa-associated microbiota profile was superior to clinical risk factors in its ability to predict POR.120 Mucosal fungal dysbiosis has also been implicated in ePOR. A 2026 study of patients who experienced early ePOR identified an increased relative abundance of Basidiomycota and increased abundance of Malassezia restricta and Debaryomyces hansenii.121 The Malassezia genus has also previously been suggested to be predictive of a poor prognosis in patients with CD.122 With further studies, stratification of gut bacterial and fungal microbiota at the time of surgery may represent a target for early individualized prophylactic treatment. To date, no studies have proven the protective effect of probiotics on ePOR, but this remains an area of ongoing interest because of our understanding of the physiopathology and predictive value of the microbiota in POR.123 Cytokines and Chemokines Cytokines are essential mediators of inflammatory processes that function via immunoregulatory signaling. Chemokines are small chemoattractant cytokines that are secreted by cells at sites of acute inflammation.124 Cytokines mediating acute inflammation include TNF, IL-1, and IL-6, which activate endothelial cells and leukocytes and facilitate systemic effects of inflammation.125–127 Most data on TNF-α levels in POR come directly from clinical trials. Infliximab, a monoclonal antibody against TNF-α, has been shown to be beneficial in preventing and treating endoscopic POR.128,129 Other studies have correlated the response to infliximab in POR directly with significant decreases in levels mucosal IL-1beta, IL-6, and TNF-a.130 An emerging area of study involving TNF-α therapies and specific mechanisms of inflammation involves the epithelial mucin, MUC1-glycoprotein. MUC1 is overexpressed in patients with POR, often in its abnormally hypoglycosylated form. MUC1 leads to upregulation of TNF-α and IL-6 expression, while TNF-α also modulates the expression of MUC1 in a positive feedback loop.131–134 Interestingly though, the increase in MUC1 associated with POR was not affected by anti-TNF use. Additional prospective studies are warranted to examine whether high MUC1 expression represents a biomarker of resistance to anti-TNF-α therapy post-operatively.135 IL-10 is a cytokine with anti-inflammatory properties (that include the suppression of pro-inflammatory cytokines such as TNF-α). The cytokine mRNA levels in ileal biopsies taken at the time of ICR demonstrated that low ileal IL-10 mRNA levels were predictive of ePOR risk.136 S. cerevisiae CNCM I-3856, the probiotic yeast discussed earlier in our discussion of microbiome factors as a candidate for the prevention of POR in AIEC-infected patients, is thought to prevent POR partly through its ability to induce IL-10 production in the intestine.116 Other cytokines implicated in POR include IL-17 and IL-23A.5 They highlighted the differences between major inflammatory cytokines and chemokines in chronic inflammatory processes present at the time of ICR (eg, IL-8, IL-1B, and IL-6) as compared to upregulation of TNF-α, IFN-γ, IL-23A, and IL-17A in early endoscopic recurrence.5 These findings highlight the distinct pathogenic inflammatory process in post-operative CD and identifying specific targets that may be of particular utility in the post-operative period. The IL-23/IL-17 pathway has been previously studied in CD, with signaling that can induce a pro-inflammatory cascade, including molecules such as TNF, IFNG, and lipopolysaccharide.14 Clinical trials of monoclonal antibodies targeting IL-17A and IL-17R have shown these therapies to be ineffective, sometimes even with worsening of the disease.15,16 However, other molecules targeting IL-23 have been approved for the treatment of luminal CD, with emerging evidence to support their clinical utility in preventing POR.17 Post-operative IL-6 and fecal lactoferrin levels are correlated, with the latter representing a proxy for intestinal inflammation.137 With simultaneous elevations in serum CRP, activation of the IL-6-CRP axis may influence post-operative systemic inflammation.137–139 Additionally, leucine-rich alpha-2 glycoprotein is a serum biomarker whose expression is induced by IL-6 and has been recently identified as a promising predictor of post-operative recurrence.140 Unfortunately, the clinical utility of IL-6 inhibitors has been marred by complications, including GI perforation and abscesses.141 Three chemokines implicated in POR include CXCL9, CXCL10, and CXCL11.9 All of which bind to the CXCR3 receptor, which is highly expressed in TH1 cells. Ligands to the CXCR3 receptor attract TH1 cells to sites of inflammation, and the CXCR3 axis is proposed to play a crucial role in T and B cell trafficking as well as effector T generation.142–145 Of these, CXCL9 was the chemokine with the strongest signal for endoscopic disease activity post-operatively, along with endopeptidase MMP1, while both CXCL9 and CXCL11 were associated with disease activity in patients with anti-TNFs. Walshe et al highlight this as a potential signal that the CXCR3 axis may have a role for “breakthrough” inflammation in POR for patients on anti-TNFs and thus represents an area deserving of additional study.9 Mitochondrial Oxidative Stress Metabolic oxidative stress has been increasingly recognized as an important factor in intestinal inflammation in addition to Crohn’s disease pathogenesis. Mechanistically, mitochondrial dysfunction leads to increased production of reactive oxygen species, which triggers intestinal barrier disruption.146 Although this field of study is still expanding, there is already developing evidence for the role of mitochondrial oxidative stress, specifically in POR pathogenesis. In a WGCNA analysis, Rajalingam et al demonstrated that the mitochondrial depolarization pathway was closely linked to development of POR given oxidative stress downstream promotes inflammation7 Ngollo et al found that upregulation of mitochondrial dysfunction and oxidative phosphorylation at the time of ICR in CD was associated with POR5 When they integrated mitochondrial dysfunction pathways into their clinical model, it strongly improved the prediction of POR. In the future, mitochondrial pathways may represent therapeutic targets for the prevention or treatment of POR in CD. Targeted Biologic Therapies Having highlighted the existing knowledge on the mechanisms of inflammation in POR, we will conclude by reviewing established and emerging clinical therapies to prevent and treat POR, with a focus on the mechanism of action. Here, we focus on biological therapies, recognizing that more conventional therapies with demonstrated efficacy in POR, such as thiopurines and antibiotics, also have such effects due to their actions on the inflammatory mechanisms discussed above. Anti-Tumor Necrosis Factor Agents As previously discussed, anti-TNF agents have demonstrated clinical benefit when used immediately post-operatively to prevent endoscopic recurrence of CD and are considered a first-line therapy post-operatively.147–149 Adalimumab (ADA) is another anti-TNF studied in POR and multiple meta-analyses have concluded the superiority of IFX and ADA to non-biologics such as thiopurines and aminosalicylates.150–157 Integrin and Interleukin Antagonists Vedolizumab (VDZ) is an integrin antagonist that binds to a4B7 integrin, selectively expressed by a subset of gastrointestinal homing T lymphocytes.158 As discussed above, T which are an essential component of intestinal inflammation in CD, blocking integrin interactions to allow T cell migration into the intestinal mucosa and hamper the inflammatory process. VDZ has been studied in a post-operative setting, and the REPREVIO randomized control trial showed that CD patients with at least one POR risk factor assigned to receive VDZ within four weeks of ICR had less severe endoscopic disease activity than the placebo group.159 Ustekinumab (UST) is a monoclonal antibody that binds to the p40 subunit, which is common to both IL-12 and IL-23. Both cytokines modulate lymphocyte function, including Th1 and Th17 cell activity, as well as cytokine production, although the specifics of their relative roles in immune pathogenesis require additional study to be clearly delineated.160 Some studies have demonstrated the comparable efficacy of UST and VDZ.161,162 JAK1 and STAT3 Inhibitors Activation of the JAK/STAT signaling pathway at the ileal margin has been shown to be predictive of POR.5 STAT3 inhibitors are in the early stages of investigation as a potential therapy for CD, although development is hindered by reservations about the consequences of inhibiting the function of STAT3 in maintaining homeostasis.22 JAK1 inhibitors currently do not have any post-operative data. Conclusion In summary, key mechanistic insights and emerging associations demonstrate that many different components of both the innate and adaptive immune systems are involved in the post-operative recurrence of Crohn’s disease following surgical resection. These mechanistic clues may drive future therapeutic and biomarker development to improve clinical outcomes in the management of CD after surgery. Future clinical practice could include routine stratification of individuals most at risk for severe POR by genetic analysis, while developing therapies could be targeted to individuals based on the mechanisms of inflammation driving recurrence. Elucidating further mechanistic processes behind some of the early associative findings in these studies on POR will be essential. Funding Statement The authors declare that no funding was received for this study. Data Sharing Statement The authors confirm that data supporting the findings of this study are available within the article. Author Contributions Hadley Greenwood Conceptualization, Investigation, Methodology, Writing – original draft. Calen Steiner Conceptualization, Supervision, Writing-review & editing. Benjamin Click Conceptualization, Supervision, Writing-review & editing. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure Dr Benjamin Click reports other from AbbVie, outside the submitted work; The authors have no other conflicts of interest to declare. References Associated Data Data Availability Statement The authors confirm that data supporting the findings of this study are available within the article.